Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab, rituximab, or insulin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:AAPS J
Huvudupphovsmän: Rosengren, Sanna, Dychter, Samuel S., Printz, Marie A., Huang, Lei, Schiff, Richard I., Schwarz, Hans-Peter, McVey, John K., Drake, Fred H., Maneval, Dan C., Kennard, Don A., Frost, Gregory I., Sugarman, Barry J., Muchmore, Douglas B.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer US 2015
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4540732/
https://ncbi.nlm.nih.gov/pubmed/25967925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-015-9782-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk